MDCK and Vero Cells for Influenza Virus Vaccine Production: a One-to-one Comparison Up to Lab-scale Bioreactor Cultivation

Overview

Journal Appl Microbiol Biotechnol

Specialties Biomedical Engineering
Biotechnology
Microbiology

Date 2010 Jul 10

PMID 20617311

Citations 37

Authors

Yvonne Genzel

Christian Dietzsch

Erdmann Rapp

Jana Schwarzer

Udo Reichl

Affiliations

Soon will be listed here.

Abstract

Over the last decade, adherent MDCK (Madin Darby canine kidney) and Vero cells have attracted considerable attention for production of cell culture-derived influenza vaccines. While numerous publications deal with the design and the optimization of corresponding upstream processes, one-to-one comparisons of these cell lines under comparable cultivation conditions have largely been neglected. Therefore, a direct comparison of influenza virus production with adherent MDCK and Vero cells in T-flasks, roller bottles, and lab-scale bioreactors was performed in this study. First, virus seeds had to be adapted to Vero cells by multiple passages. Glycan analysis of the hemagglutinin (HA) protein showed that for influenza A/PR/8/34 H1N1, three passages were sufficient to achieve a stable new N-glycan fingerprint, higher yields, and a faster increase to maximum HA titers. Compared to MDCK cells, virus production in serum-free medium with Vero cells was highly sensitive to trypsin concentration. Virus stability at 37 degrees C for different virus strains showed differences depending on medium, virus strain, and cell line. After careful adjustment of corresponding parameters, comparable productivity was obtained with both host cell lines in small-scale cultivation systems. However, using these cultivation conditions in lab-scale bioreactors (stirred tank, wave bioreactor) resulted in lower productivities for Vero cells.

Citing Articles

Replication kinetics of novel swine influenza A viruses: an approach to vaccine production.

Tapia R, Medina R, Neira V Austral J Vet Sci. 2025; 56(2):85-90.

PMID: 39991269 PMC: 11845247. DOI: 10.4206/ajvs.562.01.

Microfluidic digital focus assays for the quantification of infectious influenza virus.

Srimathi S, Ignacio M, Rife M, Tai S, Milton D, Scull M Lab Chip. 2025; .

PMID: 39907221 PMC: 11796355. DOI: 10.1039/d4lc00940a.

Serum-Free Media Formulation Using Marine Microalgae Extracts and Growth Factor Cocktails for Madin-Darby Canine Kidney and Vero Cell Cultures.

Park A, Lee Y, Jo E, Park G, Heo S, Koh E Int J Mol Sci. 2024; 25(18).

PMID: 39337368 PMC: 11432547. DOI: 10.3390/ijms25189881.

Innovations in cell culture-based influenza vaccine manufacturing - from static cultures to high cell density cultivations.

Zinnecker T, Reichl U, Genzel Y Hum Vaccin Immunother. 2024; 20(1):2373521.

PMID: 39007904 PMC: 11253887. DOI: 10.1080/21645515.2024.2373521.

From single-cell cloning to high-yield influenza virus production - implementing advanced technologies in vaccine process development.

Zinnecker T, Badri N, Araujo D, Thiele K, Reichl U, Genzel Y Eng Life Sci. 2024; 24(4):2300245.

PMID: 38584687 PMC: 10991716. DOI: 10.1002/elsc.202300245.

References

Lohr V, Rath A, Genzel Y, Jordan I, Sandig V, Reichl U . New avian suspension cell lines provide production of influenza virus and MVA in serum-free media: studies on growth, metabolism and virus propagation. Vaccine. 2009; 27(36):4975-82. DOI: 10.1016/j.vaccine.2009.05.083. View

Genzel Y, Olmer R, Schafer B, Reichl U . Wave microcarrier cultivation of MDCK cells for influenza virus production in serum containing and serum-free media. Vaccine. 2006; 24(35-36):6074-87. DOI: 10.1016/j.vaccine.2006.05.023. View

Kalbfuss B, Genzel Y, Wolff M, Zimmermann A, Morenweiser R, Reichl U . Harvesting and concentration of human influenza A virus produced in serum-free mammalian cell culture for the production of vaccines. Biotechnol Bioeng. 2006; 97(1):73-85. DOI: 10.1002/bit.21139. View

Kuster B, Wheeler S, Hunter A, Dwek R, Harvey D . Sequencing of N-linked oligosaccharides directly from protein gels: in-gel deglycosylation followed by matrix-assisted laser desorption/ionization mass spectrometry and normal-phase high-performance liquid chromatography. Anal Biochem. 1997; 250(1):82-101. DOI: 10.1006/abio.1997.2199. View

Rourou S, van der Ark A, van der Velden T, Kallel H . A microcarrier cell culture process for propagating rabies virus in Vero cells grown in a stirred bioreactor under fully animal component free conditions. Vaccine. 2007; 25(19):3879-89. DOI: 10.1016/j.vaccine.2007.01.086. View

Genzel Y, Ritter J, Konig S, Alt R, Reichl U . Substitution of glutamine by pyruvate to reduce ammonia formation and growth inhibition of mammalian cells. Biotechnol Prog. 2005; 21(1):58-69. DOI: 10.1021/bp049827d. View

Shen S, Law Y, Liu D . A single amino acid mutation in the spike protein of coronavirus infectious bronchitis virus hampers its maturation and incorporation into virions at the nonpermissive temperature. Virology. 2004; 326(2):288-98. PMC: 7126609. DOI: 10.1016/j.virol.2004.06.016. View

Merten O, Kallel H, Manuguerra J, Tardy-Panit M, Crainic R, Delpeyroux F . The new medium MDSS2N, free of any animal protein supports cell growth and production of various viruses. Cytotechnology. 2008; 30(1-3):191-201. PMC: 3449943. DOI: 10.1023/A:1008021317639. View

Schwarzer J, Rapp E, Hennig R, Genzel Y, Jordan I, Sandig V . Glycan analysis in cell culture-based influenza vaccine production: influence of host cell line and virus strain on the glycosylation pattern of viral hemagglutinin. Vaccine. 2009; 27(32):4325-36. DOI: 10.1016/j.vaccine.2009.04.076. View

10.

Schwarzer J, Rapp E, Reichl U . N-glycan analysis by CGE-LIF: profiling influenza A virus hemagglutinin N-glycosylation during vaccine production. Electrophoresis. 2008; 29(20):4203-14. DOI: 10.1002/elps.200800042. View

11.

Kessler N, Gerentes L, Aymard M . Suitability of MDCK cells grown in a serum-free medium for influenza virus production. Dev Biol Stand. 1999; 98:13-21; discussion 73-4. View

12.

Rimmelzwaan G, Baars M, Claas E, Osterhaus A . Comparison of RNA hybridization, hemagglutination assay, titration of infectious virus and immunofluorescence as methods for monitoring influenza virus replication in vitro. J Virol Methods. 1998; 74(1):57-66. DOI: 10.1016/s0166-0934(98)00071-8. View

13.

Barrett P, Mundt W, Kistner O, Howard M . Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines. Expert Rev Vaccines. 2009; 8(5):607-18. DOI: 10.1586/erv.09.19. View

14.

Toriniwa H, Komiya T . Japanese encephalitis virus production in Vero cells with serum-free medium using a novel oscillating bioreactor. Biologicals. 2007; 35(4):221-6. DOI: 10.1016/j.biologicals.2007.02.002. View

15.

Nishiyama K, Sugawara K, Nouchi T, Kawano N, Soejima K, Abe S . Purification and cDNA cloning of a novel protease inhibitor secreted into culture supernatant by MDCK cells. Biologicals. 2007; 36(2):122-33. DOI: 10.1016/j.biologicals.2007.07.004. View

16.

Kistner O, Barrett P, Mundt W, Reiter M, Dorner F . Development of a mammalian cell (Vero) derived candidate influenza virus vaccine. Vaccine. 1998; 16(9-10):960-8. DOI: 10.1016/s0264-410x(97)00301-0. View

17.

Quesney S, Marc A, Gerdil C, Gimenez C, Marvel J, Richard Y . Kinetics and metabolic specificities of Vero cells in bioreactor cultures with serum-free medium. Cytotechnology. 2008; 42(1):1-11. PMC: 3449507. DOI: 10.1023/A:1026185615650. View

18.

Merten O, Manuguerra J, Hannoun C, van der Werf S . Production of influenza virus in serum-free mammalian cell cultures. Dev Biol Stand. 1999; 98:23-37; discussion 73-4. View

19.

Tree J, Richardson C, Fooks A, Clegg J, Looby D . Comparison of large-scale mammalian cell culture systems with egg culture for the production of influenza virus A vaccine strains. Vaccine. 2001; 19(25-26):3444-50. DOI: 10.1016/s0264-410x(01)00053-6. View

20.

Genzel Y, Fischer M, Reichl U . Serum-free influenza virus production avoiding washing steps and medium exchange in large-scale microcarrier culture. Vaccine. 2006; 24(16):3261-72. DOI: 10.1016/j.vaccine.2006.01.019. View